Silence Therapeutics Plc ADR SLN

$19.71 -0.07 (-0.35%)

Valuation

Market cap
1,190,934,000
Revenue TTM
$560,000
Net income TTM
$-88,610,000
PE ratio
0.00
Forward PE
—
Profit margin
-15,823.21%
Debt to equity
0.00

Trading

Volume
2,757,800
Avg volume
2,804,892
Day's range
$19.70 – $19.79
Shares out
60,209,000
Stochastic %K
99%
Beta
1.45
Analysts
Sell
Price target
$20.40

Price

Company profile

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It a...

Show more

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Industry
Biotechnology
Sector
Healthcare
Phone
44 20 3457 6900
Website
https://www.silence-therapeutics.com
Address
12 Hammersmith Grove, London, United Kingdom

Latest news

Stocktwits

StockSmallPenz Oct 21, 5:53 PM
$NVAX I guess that rumor was false and they acquired $SLN instead.
1 replies
STRelativeStrength Oct 21, 5:50 PM
$SLN undiscovered breakout with 558 watchers
0 replies
MCRB_BULL Oct 21, 9:40 AM
$MCRB $XBI $IBB $XBI up 3.65% while MCRB drops 3.72% yesterday? Basically red every day with NO meaningful bounce since Sept 3.🤦‍♂️ Rate-hike fears and the biotech bloodbath are contributing, but ~$23M market cap, BELOW CASH, no debt, and runway through at least March 2027? We shouldn't be THIS low when the pipeline could be worth multiples of today's valuation. Look at $SLN's chart from Sept 3 through its buyout. Nearly 50% bleeding, eerily similar price action. Not saying the situations are identical, but a collapsing chart doesn't mean the underlying assets lack strategic value.👀 Could prolonged negotiations be keeping a lid on the share price? A potential acquirer may benefit from weakness. Pure speculation, but worth considering. The pipeline didn't suddenly become worthless. At ~$23M, this valuation is difficult to reconcile with the potential asset value. The longer this stays pinned down, the more I wonder what happens when that pressure finally releases. Could get WILD🚀
2 replies
Smart_investor1989 Oct 20, 3:02 PM
$GANX What I don’t understand is why some people blame bullish shareholders for their losses. Being optimistic isn’t the same as misleading others. Nobody forced anyone to buy or hold. Investing comes with risks, and we all own our decisions. I’ve chosen to hold until next year’s Phase 2 results. If it pays off, great. If not, I’ll accept the outcome. But here’s what I also don’t understand: Why do others get upset whenever management is criticized? Believing in a company doesn’t mean blindly defending it. We have every right to question the poor communication, lack of clarity on Phase 2 funding, biomarker updates, and weak PR. I believe these issues have hurt investor confidence and contributed to the stock’s decline. I’m frustrated, but I haven’t lost hope. Merck’s $1.3B deal for $SLN reminds us how quickly things can change in biotech. Nothing is guaranteed, but maybe one day it’ll be our turn. Until then, I’ll take responsibility for my decision, not someone else’s.
1 replies
sSwSs Oct 20, 2:40 PM
$SLN — Silence Therapeutics' acquisition by Merck KgaA and significant share price surge dominated recent analyses.
0 replies
VolumeSpreadAnalysis Oct 20, 1:59 PM
$SLN Price: $19.585 Volume: Average or below Catalyst: Recent investor updates on battery material technology partnerships continue to keep speculative interest alive. Resistance: $21.50 Support: $18.20 Bull case: A reclaim of $21.50 on rising volume could spark a momentum run toward prior swing highs. Bear case: A break below $18.20 support on heavier selling could open the door to retest lower $16 levels. What I'm watching: Looking for a volume surge to confirm direction before taking a stance either way. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio: @VolumeSpreadAnalysis
1 replies
AnalyticaInvestor Oct 20, 10:15 AM
$NVA $USCB $STEX Good morning, investors. Technology and semiconductors are leading market gains, with the NASDAQ rising 1.1% and semiconductors advancing 1.8%, while elevated Treasury yields continue pressuring smaller companies and capital intensive industries. Investors remain selective, favoring businesses with established revenue and manageable financing needs. On the watchlist, $NVA is advancing its Alaska gold project, while $TRCK continues showing strong YTD performance. $USCB remains supported by solid loan growth and a quarterly dividend. On the downside, $GLASF plunged 24% following disappointing preliminary results. In movers, $SLN and $EOSE recorded significant trading volume as activity accelerated across biotech and energy storage. Read the full Analytica Alpha 👇 https://analyticainvestor.beehiiv.com/p/semis-biotech-lift-market
0 replies
DataClown Oct 20, 7:34 AM
$SLN 1.41bn of ADS changed hands on a company just priced at $1.3BN, which means the money was made by whoever owned it before the press release.
0 replies